Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Pharvaris N.V. (PHVS)

Pharvaris N.V. (PHVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 743,464
  • Shares Outstanding, K 31,840
  • Annual Sales, $ 0 K
  • Annual Income, $ -109,180 K
  • 60-Month Beta -3.12
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.61
Trade PHVS with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.56
  • Number of Estimates 3
  • High Estimate -0.50
  • Low Estimate -0.64
  • Prior Year -0.72
  • Growth Rate Est. (year over year) +22.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.57 +32.90%
on 04/22/24
25.44 -8.22%
on 04/26/24
-0.34 (-1.44%)
since 03/26/24
3-Month
17.57 +32.90%
on 04/22/24
33.00 -29.24%
on 02/06/24
-6.59 (-22.01%)
since 01/26/24
52-Week
7.93 +194.45%
on 05/11/23
33.00 -29.24%
on 02/06/24
+14.15 (+153.80%)
since 04/26/23

Most Recent Stories

More News
Jobs Figures Roll out Next Week

Monday U.S. Economic Lookahead S&P U.S. manufacturing PMI (final) (Mar.) Construction ...

KNT.TO : 7.73 (+0.52%)
PVH : 111.03 (+0.22%)
SGML : 14.33 (+1.99%)
MVST : 0.4111 (+5.90%)
BRMI.TO : 0.85 (unch)
PAYX : 119.97 (-1.64%)
PLAY : 52.17 (+0.62%)
AYI : 252.16 (+0.17%)
LEVI : 21.13 (+0.19%)
PHVS : 23.35 (+2.55%)
RPM : 107.38 (+0.46%)
LW : 83.85 (+0.42%)
Why Shares of Pharvaris N.V. Are Up Tuesday

Promising news from the Food and Drug Administration spurred the healthcare stock's rise.

PHVS : 23.35 (+2.55%)
Pharvaris to Participate in H.C. Wainwright 1st Annual Hereditary Angioedema (HAE) Conference

ZUG, Switzerland, July 14, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor...

PHVS : 23.35 (+2.55%)
Pharvaris to Host Virtual Expert Perspectives on HAE: Unmet Needs and Therapeutic Options Webinar on July 13

ZUG, Switzerland, July 06, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor...

PHVS : 23.35 (+2.55%)
Pharvaris Announces Annual Meeting of Shareholders

ZUG, Switzerland, June 14, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor...

PHVS : 23.35 (+2.55%)
Pharvaris Participates in the Kinin 2022 Conference

Pharvaris’ tailored drug development approach to enable treatment of people living with all types of hereditary angioedema (HAE) presented at satellite...

PHVS : 23.35 (+2.55%)
Pharvaris Supports HAE Community by Participating in Company-wide Activities Challenge for May 16th hae day :-)

ZUG, Switzerland, May 16, 2022 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor...

PHVS : 23.35 (+2.55%)
Pharvaris Appoints Joan Schmidt, J.D., as Chief Legal Officer

Pharvaris’ executive team further strengthened by Ms. Schmidt’s deep international experience and biopharmaceutical industry tenure ZUG, Switzerland, May ...

PHVS : 23.35 (+2.55%)
Pharvaris Reports First Quarter 2022 Financial Results and Provides Business Highlights

Target enrollment achieved in RAPIDe-1, Phase 2 on-demand study of PHVS416 for the treatment of HAE attacks; top-line data anticipated in 4Q22Enrollment...

PHVS : 23.35 (+2.55%)
Pharvaris to Participate in BofA Securities 2022 Healthcare Conference

ZUG, Switzerland, May 05, 2022 (GLOBE NEWSWIRE) --  Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor...

PHVS : 23.35 (+2.55%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Pharvaris N.V. is a clinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of innovative therapies, including novel, small molecule bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema and other bradykinin-B2-receptor-mediated...

See More

Key Turning Points

3rd Resistance Point 28.37
2nd Resistance Point 26.90
1st Resistance Point 25.13
Last Price 23.35
1st Support Level 21.89
2nd Support Level 20.42
3rd Support Level 18.65

See More

52-Week High 33.00
Fibonacci 61.8% 23.42
Last Price 23.35
Fibonacci 50% 20.47
Fibonacci 38.2% 17.51
52-Week Low 7.93

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar